US should have a 'couple hundred million' doses of a Covid-19 vaccine by the start of 2021, Fauci says

The United States should have 100 million doses of one candidate coronavirus vaccine by the end of the year, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a member of the White House Coronavirus Task Force, said Tuesday.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news

Related Links:

Abstract The outbreak of the 2019 novel coronavirus (SARS-CoV-2) has infected millions of people with a large number of deaths across the globe. The existing therapies are limited in dealing with SARS-CoV-2 due to the sudden appearance of the virus. Therefore, vaccines and antiviral medicines are in desperate need. We took immune-informatics approaches to identify B- and T-cell epitopes for surface glycoprotein (S), membrane glycoprotein (M) and nucleocapsid protein (N) of SARS-CoV-2, followed by estimating their antigenicity and interactions with the human leukocyte antigen (HLA) alleles. Allergenicity, toxicity,...
Source: Virus Research - Category: Virology Authors: Tags: Virus Res Source Type: research
Before the ravaging appearance of the severe acute respiratory syndrome coronavirus 2, influenza viruses have been among the major players in the history of health disasters over the past century.1,2 Because the 1918 Spanish flu pandemic claimed more than 50 million lives followed by annual resurgence of varying degrees of morbidity and mortality, the influenza vaccine program has driven platform development and global collaborative surveillance networks. These networks support the definition of antigenic shifts that drive annual vaccine specificities for manufacturing responses.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Editorial Source Type: research
Nearly a year ago, the editors at the Annals of Allergy, Asthma&Immunology decided to put together an issue focused on vaccine technology and the importance of vaccination. At that time, we thought it was best to focus on respiratory virus vaccines (specifically for influenza and respiratory syncytial virus [RSV]), issues related to developing vaccines, and the distressing social movement against vaccination. Coronaviruses were not even considered. Now, we find ourselves in the middle of a pandemic created by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with a rush to develop...
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Editorial Source Type: research
When Dr. Anthony Fauci said in late May that there’s a “good chance” a COVID-19 vaccine will be ready by the end of this year, Steve Roth badly wanted to believe him. Roth, a 74-year-old New Yorker who endured fever, pneumonia and anxiety while fighting the virus, wants life to go back to normal as much as anyone. And he respects Fauci, the longtime head of the National Institute of Allergy and Infectious Diseases (NIAID), ”an awful lot,” he says. But he just doesn’t think Fauci’s timeline is realistic. Instead, he’s putting his proverbial money on mid 2021. “Like every...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: news
NEW BRUNSWICK, N.J., June 10, 2020 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is now expected to commence in the second half of July. Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson &Johnson, said, “Based on the strength of the preclinical data we have seen so far and interac...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
The nation ’s leading infectious disease expert tells biotech executives that Covid-19 has inflicted global damage, exposing worrisome racial disparities.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Coronavirus (2019-nCoV) Quarantines Race and Ethnicity Vaccination and Immunization National Institute of Allergy and Infectious Diseases Fauci, Anthony S your-feed-healthcare Source Type: news
Imagine you’re the person in charge of reopening New York City, and you look at the below chart: ( function() { var func = function() { var iframe = document.getElementById('wpcom-iframe-2b3181d2ed5a5c1404959ba7022ec3f8') if ( iframe ) { iframe.onload = function() { iframe.contentWindow.postMessage( { 'msg_type': 'poll_size', 'frame_id': 'wpcom-iframe-2b3181d2ed5a5c1404959ba7022ec3f8' }, "https:\/\/embeds.time.com" ); } } // Autosize iframe var funcSizeResponse = function( e ) { var origin = document.createElement( 'a' ); origin....
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
By Andrea UlrichJune 09, 2020As people around the world continue to face the effects of COVID-19, academic institutions and government policymakers are turning to data more than ever to understand the scope of the crisis, anticipate its spread, and formulate policy decisions.One example of existing high quality, real-time data is theJohns Hopkins’ COVID-19 dashboard, which has expanded as a data resource as the crisis grows. While policymakers and experts are relying on these resources, it is crucial to understand what information is being captured and what is not, as making decisions with incomplete or faulty data h...
Source: IntraHealth International - Category: International Medicine & Public Health Authors: Tags: COVID-19 Digital Health Source Type: news
(CNN) — While coronavirus keeps spreading and killing with impunity, the world waits for a vaccine that could quash the pandemic. But details and timelines keep shifting. Here’s the latest on where we stand in the race for a vaccine: When will a Covid-19 vaccine be available to the public? No one’s sure yet, but the target is sometime in early 2021. Vaccines in development around the world are in various stages of testing. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he’s confident one of the vaccine candidates will be proven safe and effective by th...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Closures Covid-19 Boston, MA Health Healthcare Status Coronavirus Coronavirus Vaccine Moderna Therapeutics Source Type: news
We present a case of a patient with immunodeficiency who has recovered from coronavirus disease 2019 (COVID-19). The patient is a 53-year-old woman who received a diagnosis of common variable immunodeficiency in 1996 and has been on regular intravenous immunoglobulin (IVIG) replacement therapy with Gamunex-C 40 g (520 mg/kg/dose) every 2 weeks. The last immunoglobulin G trough level was 1478 mg/dL on November 12, 2019, and a high-dose influenza vaccine was administered in September 2019. The patient also has hypothyroidism, bronchiectasis, and Sjogren's syndrome treated with hydroxychloroquine 400 mg daily.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research
More News: Allergy | Allergy & Immunology | Coronavirus | COVID-19 | Health | Infectious Diseases | USA Health | Vaccines